Lineage Cell Therapeutics Achieves $5 Million Milestone Payment Under Roche Agreement

-2.04%

LINEAGE CELL THERAPEUTICS INC

LCTX

1.92

-2.04%

Lineage Cell Therapeutics Inc. announced the achievement of the first development milestone under its collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. related to the OpRegen cell therapy program. This milestone, based on manufacturing and clinical advancements, triggered a $5 million milestone payment to Lineage, expected to be received within 30 days. Approximately 24.1% of the payment will be allocated to the Israel Innovation Authority and 21.5% to Hadasit Medical Research and Development Ltd., in accordance with existing agreements and regulations. OpRegen is currently in a Phase 2a clinical trial for the treatment of geographic atrophy secondary to age-related macular degeneration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-291979), on November 24, 2025, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.